Pennsylvania
CNS medication trials in Pennsylvania
77 CNS medication studies are recruiting participants at sites in 12 cities across Pennsylvania as of November 17, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every Pennsylvania city with a recruiting study
By research area: Depression (20), Parkinson's Disease (20), Migraine (10), Epilepsy (9), Schizophrenia (9), ADHD (4), Multiple Sclerosis (4), Bipolar Disorder (1).
Philadelphia (59), Pittsburgh (16), Allentown (5), Scottdale (4), Smithfield (4), Bethlehem (2), Hershey (2), West Chester (2), Willow Grove (2), Abington (1), Lancaster (1), Media (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Depression: recently updated in Pennsylvania
Basic details from each study's public record (the 12 most recently updated of 77). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Phase 3
- Ages 18 to 85
- All sexes
- Sponsor
- Cybin IRL Limited
- Recruiting in
- Philadelphia
- Registry record
- NCT06793397 · updated
Precision Depression Adalimumab Trial
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Daniel Moriarity
- Recruiting in
- Philadelphia
- Registry record
- NCT07845604 · updated
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Phase 2
- Ages 18 to 80
- All sexes
- Sponsor
- Reunion Neuroscience Inc
- Recruiting in
- Philadelphia
- Registry record
- NCT07002034 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Pennsylvania on ClinicalTrials.gov.
Parkinson's disease: recently updated in Pennsylvania
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Bethlehem
- Registry record
- NCT06623422 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Bethlehem · Philadelphia · Pittsburgh
- Registry record
- NCT06952504 · updated
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Philadelphia · Willow Grove
- Registry record
- NCT07216703 · updated
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Recruiting in
- Philadelphia · Pittsburgh
- Registry record
- NCT06989112 · updated
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Pittsburgh
- Registry record
- NCT06469944 · updated
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Lancaster
- Registry record
- NCT06345729 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Pennsylvania on ClinicalTrials.gov.
Multiple sclerosis (MS): recently updated in Pennsylvania
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Pittsburgh
- Registry record
- NCT03816345 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Pennsylvania on ClinicalTrials.gov.
Epilepsy: recently updated in Pennsylvania
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Rapport Therapeutics Inc.
- Recruiting in
- Philadelphia
- Registry record
- NCT07563881 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Pennsylvania on ClinicalTrials.gov.
Migraine: recently updated in Pennsylvania
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Phase 4
- Ages 18 to 70
- All sexes
- Sponsor
- Mayo Clinic
- Recruiting in
- Philadelphia
- Registry record
- NCT06972056 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Pennsylvania on ClinicalTrials.gov.
Ask about studies in Pennsylvania
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.
CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections